Ataxin-3 [GST-tagged] Deconjugating enzyme: Deubiquitylase

Alternate Names: Machado-Joseph disease protein 1, Spinocerebellar ataxia type 3 protein

Cat. No. 64-0033-050 Lot. No. 30076

FOR RESEARCH USE ONLY

Quantity: Storage:

eterage.

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

Protein Sequence: Please see page 2

Background

Deconjugating enzymes (DCEs) are proteases that process ubiquitin or ubiquitinlike gene products, reverse the modification of proteins by a single ubiquitin or ubiquitin-like protein (UBL) and remodel polyubiquitin (or poly-UBL) chains on target proteins (Reyes-Turcu et al., 2009). The deubiguitylating – or deubiguitinating - enzymes (DUBs) represent the largest family of DCEs and regulate ubiguitin dependent signalling pathways. The activities of the DUBs include the generation of free ubiquitin from precursor molecules, the recycling of ubiquitin following substrate degradation to maintain cellular ubiquitin homeostasis and the removal of ubiquitin or ubiquitin-like proteins (UBL) modifications through chain editing to rescue proteins from proteasomal degradation or to influence cell signalling events (Komander et al., 2009). There are two main classes of DUB; cysteine proteases and metalloproteases. Ataxin-3 is a cysteine protease and is a member of the Machado-Joseph Domain (MJD) enzyme family. Cloning of the human gene was first described by Kawaguchi et al. (1994). Machado-Joseph disease (MJD), the most common form of spinocerebellar ataxia worldwide, is a progressive and ultimately fatal neurodegenerative disorder caused by polyQ expansion in ataxin-3, a conserved and ubiquitous protein known to bind polyubiquitin chains and to function as a deubiquitylating enzyme. Ataxin-3 has been linked to protein homeostasis maintenance, transcription, cytoskeleton regulation and myogenesis (Matos et al.,

Continued on page 2

Physical Characteristics

50 µg

-70°C

Species: human

Source: E. coli

Quantity: 50 µg

Concentration: 0.5 mg/ml

Formulation: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol

Molecular Weight: ~69 kDa

Purity: >98% by InstantBlue™ SDS-PAGE

Stability/Storage: 12 months at -70°C; aliquot as required

Quality Assurance

Purity:

4-12% gradient SDS-PAGE InstantBlue™ staining Lane 1: MW markers Lane 2: 1 µg GST-Ataxin-3



Protein Identification:

Confirmed by mass spectrometry.

Deubiquitylase Enzyme Assay:

The activity of GST-Ataxin-3 was validated by determining the increase in fluorescence measured as a result of the enzyme catalysed cleavage of the fluorogenic substrate Ubiquitin-Rhodamine110-Glycine generating Ubiquitin and Rhodamine110-Glycine. Incubation of the substrate in the presence or absence of GST-Ataxin-3 was compared confirming the deubiquitylating activity of GST-Ataxin-3.



ORDERS / SALES SUPPORT International: +1-617-245-0003 US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233) Email: sales.support@ubiquigent.com UK HQ and TECHNICAL SUPPORT

 International:
 +44 (0) 1382 381147
 (9AM-5PM UTC)

 US/Canada:
 +1-617-245-0020
 (9AM-5PM UTC)

 Email:
 tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services. © Ubiquigent 2012. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

Ataxin-3 [GST-tagged] Deconjugating enzyme: Deubiquitylase

Alternate Names: Machado-Joseph disease protein 1, Spinocerebellar ataxia type 3 protein

Cat. No. 64-0033-050 Lot. No. 30076 Quantity: Storage:

Storage: -70°C

Continued from page 1

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 2 of 2

Background

Physical Characteristics

50 µg

Continued from page 1

2011). Ataxin-3 is an unusual DUB whose properties favour functional interactions with E3s such as Parkin and CHIP (Durcan et al., 2012; Scaglione et al., 2011). Ataxin-3 contains an amino-terminal protease domain followed by three Ubiguitin Interacting Motifs (UIMs) that bind longer ubiquitin chains. Ataxin-3 also trims longer chains, displaying little activity against chains of four or fewer ubiquitins (Scaglione et al., 2011). The full-length protein has been shown to preferentially cleave Lys-63-linked and mixed-linkage ubiquitin chains. This specificity is imparted by UIMs found in the enzyme C-terminal region, as the isolated Josephin domain cleaves both Lys-48 and Lys-63-linked chains with equal efficiency. Ataxin-3 can also cleave adducts at the C terminus of NEDD8, a protein that is closely related to ubiguitin in both structure and sequence (Weeks et al., 2011).

References:

Durcan TM, Kontogiannea M, Bedard N, Wing SS, Fon EA (2012) Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme. *J Biol Chem* **287**, 531-541.

Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I and et al. (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. *Nat Genet* **8**, 221-228.

Komander D, Clague MJ and Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol* **10**, 550-563.

Matos CA, de Macedo-Ribeiro S and Carvalho AL (2011) Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease. *Prog Neurobiol* **95**, 26-48.

Reyes-Turcu FE, Ventii KH and Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. *Ann Rev Biochem* **78**, 363-397.

Scaglione KM, Zavodszky E, Todi SV, Patury S, Xu P, Rodriguez-Lebron E, Fischer S, Konen J, Djarmati A, Peng J, Gestwicki JE and Paulson HL (2011) Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. *Mol Cell* **43**, 599-612. **Protein Sequence: MSPILGYWKIKGLVQPTRLLLEYLEEKYEEH** LYERDEGDKWRNKKFELGLEFPNLPYY IDGDVKLTQSMAIIRYIADKHNMLGGCP **KERAEISMLEGAVLDIRYGVSRIAYSKD** FETLKVDFLSKLPEMLKMFEDRLCHKTYLNGD HVTHPDFMLYDALDVVLYMDPMCLDAFP **KLVCFKKRIEAIPQIDKYLKSSKYIAW PLOGWOATFGGGDHPPKSD**LEVLFOG PLGSMESIFHEKOEGSLCAOHCLNN LLQGEYFSPVELSSIAHQLDEEERMR MAEGGVTSEDYRTFLOOPSGNMDDSGFF SIQVISNALKVWGLELILFNSPEYQRL RIDPINERSFICNYKEHWFTVRKLGKQWF NLNSLLTGPELISDTYLALFLAQLQQE GYSIFVVKGDLPDCEADQLLQMIRVQQMHRP KLIGEELAOLKEORVHKTDLERVLEAN DGSGMLDEDEEDLQRALALSRQEID MEDEEADLRRAIQLSMQGSSRNISQD MTQTSGTNLTSEELRKRREAY FEKQQQKQQQQQQQQQQQQQQQQQQQQGDLS GOSSHPCERPATSSGALGSDLGDAMSEEDM LQAAVTMSLETVRNDLKTEGKK

Tag (**bold text**): N-terminal GST Protease cleavage site: PreScission[™] (<u>LEVLFQ▼GP</u>) Ataxin 3 (regular text): Start **bold italics** (amino acid residues 1-370) Accession number: AAH33711

UBIQUIGENT WWW.ubiquigent.com Dundee, Scotland, UK

ORDERS / SALES SUPPORT

 International:
 +1-617-245-0003

 US Toll-Free:
 1-888-4E1E2E3 (1-888-431-3233)

 Email:
 sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

 International:
 +44 (0) 1382 381147
 (9AM-5PM UTC)

 US/Canada:
 +1-617-245-0020
 (9AM-5PM UTC)

 Email:
 tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services. © Ubiquigent 2012. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0